Refractec CK Presbyopia Treatment Should Be Limited To 2.25D – FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Refractec's CK Blended Vision radio frequency procedure should be approved to treat a narrower range of presbyobia than sought by the company, FDA's Ophthalmic Devices Panel recommended Feb. 6
You may also be interested in...
Refractec’s ViewPoint Gains FDA Approval For Limited Diopter Range
Refractec's eight direct sales reps immediately will begin marketing the ViewPoint CK system, which allows +1.0 to +2.25 diopters of presbyopia correction, as recommended by FDA's Ophthalmic Devices Panel
Refractec’s ViewPoint Gains FDA Approval For Limited Diopter Range
Refractec's eight direct sales reps immediately will begin marketing the ViewPoint CK system, which allows +1.0 to +2.25 diopters of presbyopia correction, as recommended by FDA's Ophthalmic Devices Panel
Refractec Viewpoint Hyperopia Approval Limited To Temporary Treatment
Refractec is positioning its Viewpoint CK conductive keratoplasty system as a potentially favorable alternative to LASIK for hyperopia (farsightedness) despite FDA approval limiting the product to "temporary" treatment